XNASRPRX
Market cap11bUSD
Dec 24, Last price
25.23USD
1D
-0.08%
1Q
-8.75%
IPO
-48.10%
Name
Royalty Pharma PLC
Chart & Performance
P/E
9.88
P/S
4.76
EPS
2.55
Div Yield, %
3.20%
Shrs. gr., 5y
11.23%
Rev. gr., 5y
5.58%
Revenues
2.35b
+5.24%
Net income
1.13b
+2,549.50%
CFO
2.99b
+39.36%
Dividend
Aug 16, 20240.21 USD/sh
Earnings
Feb 13, 2025
Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2,354,554 5.24% | 2,237,215 -2.28% | 2,289,463 7.89% | ||||||
Cost of revenue | 862,404 | 410,079 | 405,906 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,492,150 | 1,827,136 | 1,883,557 | ||||||
NOPBT Margin | 63.37% | 81.67% | 82.27% | ||||||
Operating Taxes | 187,232 | 762,447 | |||||||
Tax Rate | 10.25% | 40.48% | |||||||
NOPAT | 1,492,150 | 1,639,904 | 1,121,110 | ||||||
Net income | 1,134,834 2,549.50% | 42,832 -91.05% | 478,754 -3.32% | ||||||
Dividends | (358,327) | (333,322) | (285,184) | ||||||
Dividend yield | 2.12% | 1.93% | 1.73% | ||||||
Proceeds from repurchase of equity | (304,759) | ||||||||
BB yield | 1.80% | ||||||||
| Debt | |||||||||
Debt current | 997,512 | ||||||||
Long-term debt | 6,135,285 | 6,118,810 | 7,096,070 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 900 | 2,500 | (7,096,070) | ||||||
Net debt | 4,627,494 | (9,540,398) | (10,335,040) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 2,987,802 | 2,143,980 | 2,017,536 | ||||||
CAPEX | 2,041,152 | 523 | |||||||
Cash from investing activities | (2,072,789) | (1,029,421) | (1,870,280) | ||||||
Cash from financing activities | (2,148,754) | (944,856) | 385,112 | ||||||
FCF | 874,644 | 1,639,904 | 1,518,121 | ||||||
| Balance | |||||||||
Cash | 495,310 | 2,427,791 | 2,803,271 | ||||||
Long term investments | 1,012,481 | 14,228,929 | 14,627,839 | ||||||
Excess cash | 1,390,063 | 16,544,859 | 17,316,637 | ||||||
Stockholders' equity | 6,075,483 | 5,862,082 | 6,743,727 | ||||||
Invested Capital | 14,830,411 | 10,782,113 | 10,600,888 | ||||||
ROIC | 11.65% | 15.34% | 9.21% | ||||||
ROCE | 9.20% | 10.98% | 10.86% | ||||||
| EV | |||||||||
Common stock shares outstanding | 602,900 | 437,972 | 414,802 | ||||||
Price | 28.09 -28.92% | 39.52 -0.83% | 39.85 -20.38% | ||||||
Market cap | 16,935,461 -2.16% | 17,308,653 4.71% | 16,529,860 -12.04% | ||||||
EV | 25,120,747 | 11,665,478 | 10,666,771 | ||||||
EBITDA | 1,512,649 | 1,832,806 | 1,906,553 | ||||||
EV/EBITDA | 16.61 | 6.36 | 5.59 | ||||||
Interest | 187,187 | 187,961 | 166,142 | ||||||
Interest/NOPBT | 12.54% | 10.29% | 8.82% | ||||||